Terremoto Biosciences, a clinical-stage biotechnology company, has successfully closed a $108 million Series C financing round to advance its innovative pipeline. The funding will propel the clinical development of its highly selective small molecule medicines targeting cancer and rare diseases. This significant investment underscores growing confidence in the company's unique approach to inhibiting the AKT protein pathway.
Strategic Investment to Propel Clinical Trials
The financing was led by new investors including RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines. They were joined by existing backers such as OrbiMed, Third Rock Ventures, and Novo Holdings, demonstrating robust support. CEO Charles Baum expressed gratitude for the capital infusion, which will help unlock the full potential of selective AKT1 inhibition for patients.
Proceeds are earmarked to advance the company's lead programs through crucial Phase 1 clinical trials. This development phase is critical for evaluating the safety and efficacy of its novel drug candidates in humans. The funding ensures Terremoto can pursue its dual therapeutic focus on both solid tumors and the rare genetic disorder hereditary hemorrhagic telangiectasia (HHT).
A Novel Approach to Targeting the AKT Pathway
The AKT protein is a well-known driver of disease progression, but targeting it has been challenging for drug developers. Previous inhibitors in the broader PI3K/AKT pathway have often been limited by significant toxicities. These adverse effects have hindered their ability to achieve optimal therapeutic outcomes in clinical settings.
Terremoto's strategy centers on precision by targeting a specific isoform of the protein known as AKT1. Preclinical studies identify AKT1 as the predominant disease driver, while the related AKT2 isoform is linked to common side effects like rash and glucose imbalance. The company has leveraged advanced medicinal chemistry to create a new class of highly selective AKT1 inhibitors.
By selectively inhibiting AKT1 while sparing AKT2, Terremoto aims to deliver more effective and durable treatment responses. This approach is designed to overcome the dose-limiting toxicities that have plagued previous pathway inhibitors. The ultimate goal is to provide patients with a superior therapeutic benefit and an improved tolerability profile.
Advancing a Promising Dual-Pipeline
The company's lead oncology program, TER-2013, is already in Phase 1 clinical development for solid tumors. It targets cancers with specific genetic alterations in the PIK3CA, AKT, or PTEN genes. These mutations are found in a large portion of cancers, including more than half of all HR-positive breast cancer cases.
In parallel, Terremoto is advancing TER-4480 for hereditary hemorrhagic telangiectasia, a rare inherited bleeding disorder. Currently, there are no approved therapies for HHT, representing a significant unmet medical need for affected individuals. The company anticipates moving this promising program into the clinic later this year, expanding its clinical footprint.
This $108 million financing round marks a pivotal moment for Terremoto Biosciences, strongly validating its precision-based therapeutic strategy. The capital injection empowers the company to accelerate its clinical programs and move closer to delivering potentially transformative treatments. With a focus on improved efficacy and safety, Terremoto is well-positioned to make a meaningful impact on patients with cancer and rare diseases.